Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Mar 07, 2024
Mabwell's Expanded Access Policy for 9MW2821
➞
Mar 06, 2024
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
➞
Feb 25, 2024
FDA Grants Fast Track Designation to 9MW2821
➞
Feb 19, 2024
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
➞
Feb 18, 2024
FDA Grants Orphan Drug Designation to 9MW3011
➞
Feb 18, 2024
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
➞
Jan 31, 2024
Mabwell and Fudan University Shanghai Cancer Center Renew Strategic Cooperation Agreement
➞
Jan 04, 2024
Mabwell Established a Licensing and Commercialization Agreement for MAILISHU Indonesia Market
➞
Jan 02, 2024
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase
➞
上一页
1
2
3